New Jersey-based Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo Pharma USA Inc., entered into a licensing agreement with Evive Biotech a subsidiary of China’s Yifan Pharmaceutical Company Ltd., to commercialize Ryzneuta in the U.S. market.
The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is presently under late-stage evaluation by the US Food and Drug Administration for chemotherapy-induced neutropenia. Neutropenia is a side-effect of chemotherapy characterized by low counts of neutrophils, the white blood cells that fight infection.
Evive’s Marketing Authorization Application and New Drug Application for Ryzneuta are both presently under evaluation by European and Chinese regulators, too.
Evive will be responsible for the ongoing development, manufacturing, registration and supply of Ryzneuta, while Acrotech will use its sales and commercialization capabilities to market and distribute the product in the U.S.
Simon Li, CEO, Evive, said that despite the current options, chemotherapy-induced neutropenia remains a significant clinical condition for most cancer patients, creating the need for more potent and convenient treatment.
Last updated: December 26th, 2025
